PPAR

PPAR agonist4 (Compound 12) is an orally active PPAR agonist that activates PPARα, PPARδ, and PPARγ with EC50 values of 0.7 μM, 0.7 μM, and 1.8 μM, respectively. It also exhibits anti-hepatic fibrosis activity.

Anti-osteoporosis agent-10 is an inhibitor of osteoporosis that suppresses the formation of osteoclasts with an IC₅₀ of 0.042 μM. It also exhibits antagonistic activity towards PPARγ, with an EC50 value of 0.75 μM.

PPAR agonist6 (compound 5a) acts as an agonist for PPAR, exhibiting EC50 values of 3.6 μM and 2.6 μM for PPARα and PPARβ/δ respectively. Additionally, PPAR agonist6 inhibits the transactivation of a TNFα-dependent NF-κB-driven reporter gene in L929 cells [1].

A unique collection of xnum compounds targeting lipid metabolism, can be used for high-throughput screening (HTS) and high-content screening (HCS).

Sulotroban potassium is a small molecule thromboxane A2 receptor (TXA2R) antagonist that can be used to study myocardial infarction and thrombosis.

MCC-555 (Isaglitazone) is a PPARα and PPARγ agonist exerting antihyperglycemic effects.

sulotroban is a TXA2 receptor antagonist that acts synergistically with iloprost to inhibit TXA2-dependent platelet activation.

Benzo[b]thiophene-7-propanoic acid, α-methoxy-4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-, (αR)- is a dual PPARα/γ agonist with EC50 of 0.358μM and 1.21μM.

WAY-620472 is a PPAR regulator that can be used to alter the lifespan of eukaryotes.

CUDA is an effective soluble cyclohydrolase inhibitor with IC50 of 11.1 nM and 112 nM for mouse sEH and human sEH, respectively.

A unique collection of xnum nuclear receptor signaling targeted compounds for high throughput and high content screening;

CC618 is a selective PPARβ/δ antagonist with an IC50 of 10.0 μM.

AZD-9574 is a selective inhibitor of PARP1 at the sites of SSBs.

Hydrangeic acid is an orally effective stilbene-type glycolipid metabolism regulator that lowers blood glucose and lipids. This compound can be isolated from processed leaves of Hydrangea macrophylla var. thunbergii. It is linked to glucose-lipid metabolism and insulin sensitivity regulation. Hydrangeic acid does not directly activate PPARγ or PPARα; instead, it enhances the mRNA expression of adiponectin, PPARγ2, GLUT4, and fatty acid-binding protein aP2 while reducing TNF-α mRNA levels, thereby promoting adipogenesis, glucose uptake, and GLUT4 translocation in 3T3-L1 cells. Additionally, it suppresses the production of NO induced by inflammatory factors, improving insulin resistance. Hydrangeic acid is useful for research related to type 2 diabetes and does not cause liver weight gain.

PPAR alpha/PPARA Protein, Human, Recombinant (His) is expressed in E.

CP-868388 free base (CP-868388) is a PPARα agonist with hypolipidemic and anti-inflammatory activity and is used in the study of dyslipidemia.

Balaglitazone is a PPARγ agonist that regulates blood glucose and is used in studies of heart failure and myocardial infarction.

PPAR alpha/PPARA Protein, Mouse, Recombinant (His) is expressed in E.

Candesartan-d4 is the deuterated Candesartan; AT1 receptor blocker and PPAR-γ agonist; antihypertensive; internal standard for PK analysis.

Cinnamyl Alcohol (Standard) is the standard substance of Cinnamyl Alcohol, and it is applicable for quantitative analysis, quality control, and related research in biochemical experiments. Cinnamyl alcohol (Styryl Carbinol) readily autoxidizes upon air exposure, and forms strong sensitizers as determined by the local lymph node assay.